Cargando…
The Immunology of Hormone Receptor Positive Breast Cancer
Immune checkpoint blockade (ICB) has revolutionized the treatment of cancer patients. The main focus of ICB has been on reinvigorating the adaptive immune response, namely, activating cytotoxic T cells. ICB has demonstrated only modest benefit against advanced breast cancer, as breast tumors typical...
Autores principales: | Goldberg, Jonathan, Pastorello, Ricardo G., Vallius, Tuulia, Davis, Janae, Cui, Yvonne Xiaoyong, Agudo, Judith, Waks, Adrienne G., Keenan, Tanya, McAllister, Sandra S., Tolaney, Sara M., Mittendorf, Elizabeth A., Guerriero, Jennifer L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202289/ https://www.ncbi.nlm.nih.gov/pubmed/34135901 http://dx.doi.org/10.3389/fimmu.2021.674192 |
Ejemplares similares
-
Quality Control for Single Cell Analysis of High-plex Tissue Profiles using CyLinter
por: Baker, Gregory J., et al.
Publicado: (2023) -
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
por: Waks, Adrienne G, et al.
Publicado: (2022) -
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2021) -
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
por: Keenan, Tanya E., et al.
Publicado: (2021) -
Author Correction: Virtual clinical trials identify effective combination therapies in ovarian cancer
por: Kozłowska, Emilia, et al.
Publicado: (2020)